$EDSA News

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

Edesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo

EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway

Edesa Biotech Stock Sinks After Fresh Capital Raise

Edesa Biotech Stock Sinks After Fresh Capital Raise

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

Edesa Biotech Announces Proposed Public Offering

Edesa Biotech Commences Common Stock Offering; Terms Undisclosed

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Edesa Biotech Q3 EPS $(0.60) Misses $(0.58) Estimate

EDSA: Positive Exploratory Data in Patients with AKI

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

Edesa Biotech Announces Exploratory Data For Its Anti-TLR4 Monoclonal Antibody Paridiprubart In Patients With Acute Kidney Injury And Respiratory Distress; Analyses Demonstrate Mortality Reduction

Edesa Biotech, Inc. (EDSA) Presents at Dermatology Drug Development Summit 2026 - Slideshow

EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial

EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial

Edesa Biotech, Inc. (EDSA) Presents at Respiratory Innovation Summit 2026 - Slideshow

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results